Advanced Cancer Therapeutics' business strategy
is to leverage an innovative arrangement with the James Graham Brown
Cancer Center and the breakthrough discoveries made by the more than
fifty research scientists who work there. Utilizing
premier contract research organizations (CRO's), ACT will identify, select and
rapidly advance the most promising anti-cancer products from the preclinical
stage of development through completion of Phase I clinical trials.
ACT will then evaluate various
value-driven strategic options for further advancement of these products into
mid and late stage clinical trials in anticipation of reaching the
market expeditiously. Every new biotechnology company has a business
plan or strategy, but through its unique
business relationship with The James Graham Brown Cancer Center, Advanced Cancer
Therapeutics is uniquely positioned to advance the most appealing discoveries
among a portfolio of products and make a positive impact in the lives
of cancer patients.
What Differentiates ACT from Other Biotechnology Companies?